

IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Cancelled)

Claim 2. (Currently Amended) ~~A compound as described in claim 1~~ Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate, which is in the form of crystals.

Claim 3. (Currently Amended) ~~A compound as described in claim 1 or 2~~ Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate, which is in the form of plate-like crystals.

Claim 4. (Currently Amended) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate ~~A compound as described in claim 1~~, which is in the form of Type-II crystals having the full XRD pattern of FIG. 4.

Claim 5. (Currently Amended) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate ~~A compound as described in claim 1 or 2~~, which is in the form of needles.

Claim 6. (Currently Amended) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate ~~A compound as described in claim 1~~, which is in the form of Type I crystals having the full XRD pattern of FIG. 4 [[5]].

Claim 7 (Cancelled).

Claims 8-17 (Cancelled).

Claim 18 (Currently Amended) A medicine containing, as an active ingredient, a compound as described in claim 4 and wherein the medicine is in a form selected from the group consisting of a tablet, powder, granule, and capsule.

Claim 19 (Cancelled).